相关实验视频
Updated: Jun 11, 2025

08:55
A Novel In Vitro Wound Healing Assay to Evaluate Cell Migration
Published on: March 17, 2018
21.9K
埃斯对布拉迪基宁通路的作用:一个未知的机制的有利临床特性?
Gianmarco Marcianò1, Cristina Vocca1, Demirhan Dıraçoğlu2
1Operative Unit of Pharmacology and Pharmacovigilance, "Renato Dulbecco" University Hospital, 88100 Catanzaro, Italy.
Antioxidants (Basel, Switzerland)
|September 28, 2024
概括
来自马栗的埃斯,可以减少胀和炎症. 它独特地抑制了布拉迪基宁通路,为诸如静脉缺陷等疾病提供治疗优势.
科学领域:
- 药理学 药理学是指药理学的学科.
- 自然产品 自然产品
- 炎症研究 炎症研究
背景情况:
- 埃斯是一种来自马栗 (Aesculus hippocastanum) 的化合物,具有显著的抗和抗炎性质.
- 它在临床上应用于管理静脉功能不充分,疼痛,炎症和.
- 它的独特机制涉及布拉迪基宁通路,使其与其他治疗剂有所区别.
研究的目的:
- 审查埃斯的药理作用,重点关注其对布拉迪基宁通路的影响.
- 突出ESCIN在治疗和炎症方面的治疗潜力.
- 提供与布拉迪基宁有关的escin的作用机制的概述.
主要方法:
- 关于埃斯和布拉迪基宁通路的现有文献的叙事综述.
- 分析escin. 的药学动力学特性.
- 综合了有关埃斯抗炎和抗作用的数据.
主要成果:
- 埃斯显示出强大的抗和抗炎活性.
- 一个关键的药理动力学效应是抑制布拉迪基宁通路.
- 这种抑制导致局部胀减少,并提供治疗优势.
结论:
- 埃斯对布拉迪基宁通路的抑制是其治疗益处的关键机制.
- 埃斯是一种有价值的化合物,用于治疗和炎症,特别是在静脉功能不全.
- 对埃斯的布拉迪基宁调节效应的进一步研究可能会发现新的治疗应用.
相关概念视频
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
490
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
490
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
137
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
137
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
395
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
395
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
540
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
540
Antihypertensive Drugs: Action of β1 Blockers
312
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
312
Antihypertensive Drugs: Angiotensin II Receptor Blockers
597
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
597

